Innovation Lifestyle and Mind Pharma & Biotechnology Press Preventive Health

AstraZeneca ties up with Emergent BioSolutions to make COVID-19 vaccine in U.S.

Emergent BioSolutions Inc said on Thursday it signed an $87 million deal to make AstraZeneca Plc’s experimental COVID-19 vaccine in the United States, boosting the British drugmaker’s efforts to bring a vaccine to the market.

The deal comes weeks after the United States pledged up to $1.2 billion to secure 300 million doses of AstraZeneca’s vaccine, which is among the first to move into mid-stage trials.

AstraZeneca has said that the first indication of the effectiveness of its vaccine would likely be available in June or July. However, experts have cautioned that a safe and effective vaccine could take at least 12 to 18 months from the start of development.

Under the agreement, Emergent said large-scale manufacturing of the vaccine will be done at its Baltimore Bayview facility, which has the capacity to produce up to hundreds of millions of doses annually.

Read More

Meeta Ramnani
Meeta Ramnani
Meeta develops credible content about various markets based on deep research, opinions from experts and inputs from industry leaders. As the managing editor at Smart Industry News, she assures that every piece of news and article adds to the knowledge of decision makers. An avid bike rider, Meeta, is a postgraduate from Indian Institute of Journalism and New Media (IIJNM) Bangalore, where her specialization was Business Journalism. She carries experience from mainstream print media including The Times Group and Sakal Media Group.
https://smarthealthcarenews.com/